Chromocell Therapeutics Corporation develops non-opioid therapeutics targeting the NaV1.7 sodium ion channel to treat chronic and acute pain conditions. Their portfolio includes sublingual and intranasal spray devices designed for mild to moderate pain, acute migraines, and nausea related to chemotherapy and surgery.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic and acute pain conditions often rely on opioid-based treatments, which carry significant risks of addiction, tolerance, and adverse side effects. Current non-opioid pain management options may lack efficacy or have limited applicability for certain patient populations and pain types.
Solution
Chromocell Therapeutics is developing non-opioid therapeutics that target the NaV1.7 sodium ion channel for the treatment of chronic and acute pain. Their approach focuses on selectively modulating NaV1.7, a validated pain target, to reduce pain signaling without the liabilities associated with opioids. The company is developing a portfolio of novel formulations and delivery methods, including sublingual and intranasal sprays, designed to provide rapid and effective pain relief for a range of conditions. These delivery methods aim to improve patient compliance and offer a non-invasive alternative to traditional pain medications.
Target Audience
The primary target audience includes individuals suffering from chronic and acute pain, migraine sufferers, and patients experiencing nausea related to chemotherapy or surgery.
Features
- Selective NaV1.7 sodium ion channel modulation for targeted pain relief
- Development of non-opioid therapeutics to avoid addiction and tolerance issues
- Sublingual spray formulation for rapid absorption and onset of action
- Intranasal spray delivery for convenient and non-invasive administration
- Pipeline focused on chronic and acute pain, acute migraines, and chemotherapy/surgery-related nausea